

APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027

Market Report | 2023-01-10 | 154 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The Asia Pacific in situ hybridization market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.

"The kits & reagents segment accounted for the highest share in the Asia Pacific ISH consumables market revenue for the year 2021"

The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.

"Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021"

Based on the end users the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

end-user segment.

?

"China: The fastest-growing country in the Asia Pacific in situ hybridization market"

The Asia Pacific in situ hybridization market is segmented into Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific. China market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the country, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the country. The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 80% and Demand Side 20%

-□By Designation: C-level - 25%, D-level - 20%, and Others - 55%

Lists of Companies Profiled in the Report:

-□Abbott (US)

-□Abbott Laboratories (US)

-□Thermo Fisher Scientific (US)

-□Danaher Corporation (US)

-□Merck (Germany)

-□F. Hoffmann-La Roche (Switzerland)

-□BioView (Israel)

-□Agilent Technologies (US)

-□Biocare Medical (US)

-□Bio-Techne Corporation (US)

-□QIAGEN (Germany)

-□PerkinElmer (US)

-□Enzo Biochem (US)

-□Bio-Rad Laboratories (US)

-□Abnova Corporation (Taiwan)

-□BioGenex Laboratories (US)

-□OpGen (US)

-□Bio SB (US)

-□Abcam (UK)

-□Zytomed (Germany)

-□10x Genomics Inc. (US)

-□NeoGenomics Laboratories (US).

Research Coverage:

This report provides a detailed picture of the Asia Pacific in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and country. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	22
1.1	STUDY OBJECTIVES	22
1.2	MARKET DEFINITION	22
1.2.1	INCLUSIONS & EXCLUSIONS	22
1.3	MARKET SCOPE	23
1.3.1	MARKETS COVERED	23
1.4	YEARS CONSIDERED	23
1.5	CURRENCY CONSIDERED	24
1.6	LIMITATIONS	24
1.7	STAKEHOLDERS	24
1.8	SUMMARY OF CHANGES	24
2	RESEARCH METHODOLOGY	25
2.1	RESEARCH DATA	25
	FIGURE 1 RESEARCH DESIGN	25
2.1.1	SECONDARY DATA	25
2.1.2	PRIMARY DATA	26
	FIGURE 2 BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET	26
2.2	MARKET ESTIMATION METHODOLOGY	27
	FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)	27
	FIGURE 4 APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION)	27
	FIGURE 5 APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022-2027)	28
	FIGURE 6 APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES	28
2.3	MARKET DATA ESTIMATION & TRIANGULATION	29
	FIGURE 7 DATA TRIANGULATION METHODOLOGY	29
2.4	INDUSTRY INSIGHTS	30
2.5	RESEARCH ASSUMPTIONS	30
3	EXECUTIVE SUMMARY	31
	FIGURE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)	31
	FIGURE 9 APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2021	31
	FIGURE 10 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)	32
	FIGURE 11 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021	32
	FIGURE 12 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)	33
4	PREMIUM INSIGHTS	34
4.1	APAC IN SITU HYBRIDIZATION MARKET OVERVIEW	34
	FIGURE 13 GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH	34
4.2	APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)	35
	FIGURE 14 HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD	35
5	MARKET OVERVIEW	36
5.1	INTRODUCTION	36
5.2	MARKET DYNAMICS	36
	FIGURE 15 APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES	36
	TABLE 1 APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS	37
5.2.1	DRIVERS	37
5.2.1.1	Increasing incidence of genetic disorders and cancer	37
	TABLE 2 NEW CASES OF CANCER IN ASIA, 2020 VS. 2025	37
	FIGURE 16 HEMOPHILIA OCCURRENCE, BY REGION	38

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1.2	Growing awareness about companion diagnostics	38
5.2.2	OPPORTUNITIES	38
5.2.2.1	Untapped markets in developing countries	38
5.2.3	CHALLENGES	39
5.2.3.1	Shortage of skilled professionals	39
5.3	PORTER'S FIVE FORCES ANALYSIS	39
TABLE 3 APAC IN SITU HYBRIDIZATION MARKET: PORTER'S FIVE FORCES ANALYSIS		
5.3.1	THREAT FROM NEW ENTRANTS	39
5.3.2	THREAT FROM SUBSTITUTES	39
5.3.3	BARGAINING POWER OF BUYERS	40
5.3.4	BARGAINING POWER OF SUPPLIERS	40
5.3.5	INTENSITY OF COMPETITIVE RIVALRY	40
5.4	SUPPLY CHAIN ANALYSIS	40
FIGURE 17 SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET		
5.5	VALUE CHAIN ANALYSIS	42
FIGURE 18 VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET		
5.6	ECOSYSTEM ANALYSIS	43
FIGURE 19 ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET		
5.7	KEY CONFERENCES & EVENTS IN 2022-2023	43
TABLE 4 KEY CONFERENCES & EVENTS, 2022-2023		
5.8	REGULATORY ANALYSIS	44
5.8.1	FDA APPROVALS	44
5.8.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	44
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS		
5.9	PRICING ANALYSIS	45
TABLE 6 PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS		
5.9.1	APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS	45
TABLE 7 PRICING ANALYSIS OF FISH TESTS IN INDIA (2021)		
5.10	KEY STAKEHOLDERS AND BUYING CRITERIA	47
5.10.1	KEY STAKEHOLDERS IN BUYING PROCESS	47
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC		
5.10.2	BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC	48
FIGURE 21 KEY BUYING CRITERIA FOR END USERS		
6	APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT	49
6.1	INTRODUCTION	50
TABLE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)		
6.2	CONSUMABLES	50
TABLE 9 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION)		
TABLE 10 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION)		
6.2.1	PROBES	51
6.2.1.1	Growing preference for direct localization of DNA/RNA sequences using probes to drive market	51
TABLE 11 APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION)		
6.2.2	KITS & REAGENTS	52
6.2.2.1	Growing focus on companion diagnostics to boost demand	52
TABLE 12 APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)		
6.2.3	ACCESSORIES	52
6.2.3.1	Use of accessories for optimal performance of FISH and CISH probes to propel adoption	52

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 13	APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION)	53
6.3	INSTRUMENTS	53
6.3.1	RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET	53
TABLE 14	APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)	54
6.4	SOFTWARE	54
6.4.1	GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET	54
TABLE 15	APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)	55
7	APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION	56
7.1	INTRODUCTION	57
TABLE 16	APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	57
7.2	CANCER DIAGNOSTICS	57
7.2.1	GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET	57
TABLE 17	APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)	58
7.3	CYTOLOGY	58
7.3.1	GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET	58
TABLE 18	APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)	59
7.4	INFECTIOUS DISEASE DIAGNOSTICS	59
7.4.1	NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH	59
TABLE 19	APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)	60
7.5	NEUROSCIENCE	60
7.5.1	RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES	60
TABLE 20	APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)	61
7.6	IMMUNOLOGY	61
7.6.1	RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH	61
TABLE 21	APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)	62
8	APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY	63
8.1	INTRODUCTION	64
TABLE 22	APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	64
8.2	FLUORESCENCE IN SITU HYBRIDIZATION (FISH)	64
TABLE 23	APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)	64
TABLE 24	APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	65
8.2.1	DNA FLUORESCENCE IN SITU HYBRIDIZATION	65
8.2.1.1	Need to ensure stability of genetic material to drive market	65
TABLE 25	APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	66
8.2.2	RNA FLUORESCENCE IN SITU HYBRIDIZATION	66
8.2.2.1	Increasing biomedical research to support market growth	66
TABLE 26	APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	67
8.2.3	PNA FLUORESCENCE IN SITU HYBRIDIZATION	67
8.2.3.1	Increased applications in infectious disease diagnosis to boost market	67
TABLE 27	APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	68
8.3	CHROMOGENIC IN SITU HYBRIDIZATION (CISH)	68
8.3.1	COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH	68
TABLE 28	APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	69
9	APAC IN SITU HYBRIDIZATION MARKET, BY END USER	70
9.1	INTRODUCTION	71
TABLE 29	APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)	71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.2 HOSPITAL & DIAGNOSTIC LABORATORIES 71

9.2.1 GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET 71

TABLE 30 APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION) 72

9.3 ACADEMIC & RESEARCH INSTITUTES 72

9.3.1 GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET 72

TABLE 31 APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 73

9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 73

9.4.1 NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH 73

TABLE 32 APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 74

9.5 CONTRACT RESEARCH ORGANIZATIONS 74

9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET 74

TABLE 33 APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 75

10 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY 76

10.1 INTRODUCTION 77

FIGURE 22 APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT 77

TABLE 34 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

10.1.1 JAPAN 78

10.1.1.1 Growing focus on personalized diagnostics to support market growth 78

TABLE 35 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 79

TABLE 36 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 79

TABLE 37 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 79

TABLE 38 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 80

TABLE 39 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 40 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 80

10.1.2 CHINA 81

10.1.2.1 China to register highest CAGR during forecast period 81

TABLE 41 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 81

TABLE 42 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 81

TABLE 43 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 82

TABLE 44 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 82

TABLE 45 CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 46 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 83

10.1.3 INDIA 83

10.1.3.1 Collaborations between hospitals and diagnostic labs to propel market growth in India 83

TABLE 47 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 83

TABLE 48 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 84

TABLE 49 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 84

TABLE 50 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 84

TABLE 51 INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 52 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 85

10.1.4 SOUTH KOREA 85

10.1.4.1 Robust healthcare infrastructure to boost growth 85

TABLE 53 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 86

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 54 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 86

TABLE 55 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 86

TABLE 56 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 87

TABLE 57 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 87

TABLE 58 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 87

10.1.5 TAIWAN 88

10.1.5.1 Improving cancer research and care to propel demand for ISH 88

TABLE 59 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 88

TABLE 60 TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 88

TABLE 61 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 89

TABLE 62 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 89

TABLE 63 TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 64 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90

10.1.6 SINGAPORE 90

10.1.6.1 Government initiatives to make cancer treatment more affordable to contribute to growth 90

TABLE 65 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 90

TABLE 66 SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 91

TABLE 67 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 91

TABLE 68 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 91

TABLE 69 SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 70 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 92

10.1.7 AUSTRALIA 93

10.1.7.1 Increasing public-private investments in cancer research to boost demand 93

TABLE 71 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 93

TABLE 72 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 73 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 94

TABLE 74 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 94

TABLE 75 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 76 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 95

10.1.8 NEW ZEALAND 95

10.1.8.1 Rising cases of cancer to propel growth 95

TABLE 77 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 96

TABLE 78 NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 79 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 96

TABLE 80 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 97

TABLE 81 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 82 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 97

10.1.9 REST OF ASIA PACIFIC 98

TABLE 83 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 98

TABLE 84 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 98

TABLE 85 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 99

TABLE 86 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 99

TABLE 87 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION) 99

TABLE 88 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 100

11 COMPETITIVE LANDSCAPE 101

11.1 INTRODUCTION 101

11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS 101

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 89 APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 101

11.3 MARKET SHARE ANALYSIS 102

FIGURE 23 APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021) 102

11.4 REVENUE SHARE ANALYSIS 103

FIGURE 24 REVENUE ANALYSIS OF KEY COMPANIES (2019-2021) 103

11.5 COMPANY EVALUATION QUADRANT 104

11.5.1 STARS 104

11.5.2 EMERGING LEADERS 104

11.5.3 PERVASIVE PLAYERS 104

11.5.4 PARTICIPANTS 104

FIGURE 25 APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021) 105

11.6 COMPETITIVE SCENARIO AND TRENDS 106

11.6.1 PRODUCT LAUNCHES 106

TABLE 90 APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019-2022 106

11.6.2 DEALS 107

TABLE 91 APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019-2022 107

?

12 COMPANY PROFILES 108

12.1 KEY COMPANIES 108

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

12.1.1 ABBOTT LABORATORIES 108

TABLE 92 ABBOTT LABORATORIES: BUSINESS OVERVIEW 108

FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 109

12.1.2 F. HOFFMANN-LA ROCHE AG 111

TABLE 93 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 111

FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 112

12.1.3 THERMO FISHER SCIENTIFIC, INC. 114

TABLE 94 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 114

FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 115

12.1.4 DANAHER CORPORATION 117

TABLE 95 DANAHER CORPORATION: BUSINESS OVERVIEW 117

FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 118

12.1.5 AGILENT TECHNOLOGIES, INC. 120

TABLE 96 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 120

FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 121

12.1.6 BIOCARE MEDICAL 123

TABLE 97 BIOCARE MEDICAL: BUSINESS OVERVIEW 123

12.1.7 BIO-TECHNE CORPORATION 125

TABLE 98 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 125

FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 126

12.1.8 QIAGEN N.V. 128

TABLE 99 QIAGEN N.V.: BUSINESS OVERVIEW 128

FIGURE 32 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 129

12.1.9 MERCK KGAA 130

TABLE 100 MERCK KGAA: BUSINESS OVERVIEW 130

FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021) 131

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.10	PERKINELMER	132
	TABLE 101	PERKINELMER: BUSINESS OVERVIEW
	FIGURE 34	PERKINELMER: COMPANY SNAPSHOT (2021)
12.1.11	ENZO BIOCHEM	134
	TABLE 102	ENZO BIOCHEM: BUSINESS OVERVIEW
	FIGURE 35	ENZO BIOCHEM: COMPANY SNAPSHOT (2021)
12.1.12	BIO-RAD LABORATORIES	137
	TABLE 103	BIO-RAD LABORATORIES: BUSINESS OVERVIEW
	FIGURE 36	BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.13	ABNOVA CORPORATION	139
	TABLE 104	ABNOVA CORPORATION: BUSINESS OVERVIEW
12.1.14	BIOGENEX LABORATORIES	140
	TABLE 105	BIOGENEX LABORATORIES: BUSINESS OVERVIEW
12.1.15	OPGEN INC.	142
	TABLE 106	OPGEN INC.: BUSINESS OVERVIEW
	FIGURE 37	OPGEN INC.: COMPANY SNAPSHOT (2021)
12.1.16	BIO SB	144
	TABLE 107	BIO SB: BUSINESS OVERVIEW
12.1.17	ABCAM	145
	TABLE 108	ABCAM: BUSINESS OVERVIEW
	FIGURE 38	ABCAM: COMPANY SNAPSHOT (2021)
12.1.18	ZYTOMED SYSTEMS GMBH	147
	TABLE 109	ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
12.1.19	NEOGENOMICS LABORATORIES	148
	TABLE 110	NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
	FIGURE 39	NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.20	BIOVIEW	150
	TABLE 111	BIOVIEW: BUSINESS OVERVIEW
	FIGURE 40	BIOVIEW: COMPANY SNAPSHOT (2021)
12.1.21	10X GENOMICS	151
	TABLE 112	10X GENOMICS: BUSINESS OVERVIEW
	FIGURE 41	10X GENOMICS: COMPANY SNAPSHOT (2021)

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

13	APPENDIX	153
13.1	DISCUSSION GUIDE	153
13.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	155
13.3	CUSTOMIZATION OPTIONS	157
13.4	RELATED REPORTS	157
13.5	AUTHOR DETAILS	158

APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027

Market Report | 2023-01-10 | 154 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com